全文获取类型
收费全文 | 1776篇 |
免费 | 109篇 |
国内免费 | 46篇 |
专业分类
耳鼻咽喉 | 23篇 |
儿科学 | 93篇 |
妇产科学 | 11篇 |
基础医学 | 130篇 |
口腔科学 | 58篇 |
临床医学 | 154篇 |
内科学 | 273篇 |
皮肤病学 | 40篇 |
神经病学 | 50篇 |
特种医学 | 155篇 |
外科学 | 180篇 |
综合类 | 240篇 |
预防医学 | 119篇 |
眼科学 | 23篇 |
药学 | 153篇 |
中国医学 | 78篇 |
肿瘤学 | 151篇 |
出版年
2023年 | 11篇 |
2022年 | 22篇 |
2021年 | 37篇 |
2020年 | 28篇 |
2019年 | 21篇 |
2018年 | 30篇 |
2017年 | 41篇 |
2016年 | 25篇 |
2015年 | 47篇 |
2014年 | 70篇 |
2013年 | 97篇 |
2012年 | 130篇 |
2011年 | 130篇 |
2010年 | 107篇 |
2009年 | 99篇 |
2008年 | 122篇 |
2007年 | 106篇 |
2006年 | 87篇 |
2005年 | 72篇 |
2004年 | 58篇 |
2003年 | 51篇 |
2002年 | 46篇 |
2001年 | 42篇 |
2000年 | 37篇 |
1999年 | 34篇 |
1998年 | 29篇 |
1997年 | 32篇 |
1996年 | 29篇 |
1995年 | 18篇 |
1994年 | 11篇 |
1993年 | 17篇 |
1992年 | 13篇 |
1991年 | 17篇 |
1990年 | 19篇 |
1989年 | 20篇 |
1988年 | 21篇 |
1987年 | 16篇 |
1986年 | 16篇 |
1985年 | 19篇 |
1984年 | 10篇 |
1983年 | 9篇 |
1982年 | 13篇 |
1981年 | 12篇 |
1980年 | 9篇 |
1979年 | 5篇 |
1978年 | 7篇 |
1977年 | 7篇 |
1976年 | 4篇 |
1975年 | 8篇 |
1968年 | 5篇 |
排序方式: 共有1931条查询结果,搜索用时 0 毫秒
1.
Increased arterial stiffness in young normotensive patients with Turner syndrome: associations with vascular biomarkers 下载免费PDF全文
2.
3.
Statutory reimbursement agencies as well as private insurers throughout member states of the Organization for Economic Cooperation and Development (OECD) reimburse the cost of medicines on the basis of criteria that include robust clinical evidence, budget impact analysis, and incremental cost effectiveness. The Centers for Medicare and Medicaid Services (CMS) in the US are no exception to this rule and are, in principle, seeking to maximize benefit for their Medicare enrollees, whilst ensuring reasonable drug outlays for the small number of drugs that they reimburse. This paper provides a retrospective analysis of the way two functionally equivalent drugs are treated for reimbursement purposes by the CMS; the period under consideration was 2001–3. The two drugs, epoetin-α and darbepoetin-α, are used for the treatment of anemia in renal failure and in patients receiving chemotherapy. By reviewing the publicly available pharmacological and clinical data of epoetin-α and darbepoetin-α, the paper confirms the two drugs’ functional equivalence, despite their structural differences. The implications of dose conversion ratios and costs to Medicare are subsequently explored. It is argued that the issue of dose equivalence between epoetin-α and darbepoetin-α has significant implications for patients, practitioners, and payors. A payor’s perspective is adopted in this respect, whereby clinical evidence and pricing data are used simultaneously. Based on the clinical evidence, a dose conversion ratio for epoetin-α:darbepoetin-α is established, which achieves a comparable clinical effect for the two drugs and this is set to be <254IU:1μg. The incremental costs to Medicare are calculated subsequently. The Average Wholesale Price and the Outpatient Prospective Payment System rule that Medicare uses to reimburse providers are used and suggest that treatment of cancer patients with chemotherapy-related anemia with epoetin-α would save Medicare an estimated $US600 million each year. Patients would also benefit significantly in terms of lower co-payments for epoetin-α. The evidence is supportive of the decision made by the CMS to reimburse the two drugs at the rate reflecting the achievement of comparable clinical effects and therefore reducing the pass-through payments for darbepoetin-α to zero for the 2002–3 fiscal year. 相似文献
4.
K Naito H Hisazumi A Saka T Nakamura S Kanda I Mikawa S Ejiri T Miyagi T Katsumi K Kitagawa 《Hinyokika kiyo. Acta urologica Japonica》1990,36(4):487-494
To evaluate the effect of UFT, a mixture of ftorafur and uracil in a ratio of 1:4, in preventing postoperative recurrence of bladder cancer, we performed a randomized controlled study with a non-medication group as control. UFT was given orally 400 mg a day for 6 months. Of 111 patients, 56 were given UFT and 55 were followed up without any medication. The non-recurrence rate in the group treated with UFT was 62.8% after 1 year and 36.3% after 2 years of follow up, and that of the control group was 45.7% and 39.5%, respectively. The rate of non-recurrence in the UFT group was significantly higher (p less than 0.05) than that of the control group during the period of follow up for 2 years. The incidence of side effects was 6.8% in UFT patients. These results indicate the clinical usefulness of prophylactic administration of UFT for bladder cancer patients. 相似文献
5.
HA Carpay P Matthijsse M Steinbuch PGH Mulde 《Cephalalgia : an international journal of headache》1997,17(5):591-595
In an open, randomized cross-over study in 124 patients, we compared the efficacy, safety and patient preference of oral and subcutaneous sum triptan in the acute treatment of migraine. Patients were treated for 3 attacks or 3 months and then crossed over. Primary clinical efficacy was defined as a reduction in headache severity on a four-point self-rating scale from severe (3) or moderate (2) to mild (1) or none (0), or mild (1) to none (0). Efficacy was evaluated 2 h after the administration of subcutaneous and 4h after the administration of oral sumatriptan. Subcutaneous sumatriptan was significantly more effective than oral sumatriptan in relieving headache (over all three attacks 78% vs 61% improvement), improving clinical disability (55% vs 41 % improvement) and relieving nausea (69% vs 53%), vomiting (72% vs 32%) and phono- or photophobia (67% vs 49%). Median time to recurrence was shorter after subcutaneous (12.5 h) than after oral sumatriptan (18 h); the number of patients experiencing a recurrence was similar Patients reported more adverse events after subcutaneous sumatriptan (1.32 per attack) than after the oral form (0.85 per attack), but all adverse events were mild to moderate in intensity and of short duration. Patient opinion was more often positive after subcutaneous sumatriptan. These results may be useful in counselling patients to choose between the available marketed formulations of sumatriptan. 相似文献
6.
Modern surgery for gastric cancer--Japanese perspective. 总被引:1,自引:0,他引:1
7.
8.
9.
超细β-磷酸三钙/聚-L-乳酸复合材料的制备与骨折内固定器的加工 总被引:3,自引:0,他引:3
目的:制备分散性良好的超细β-磷酸三钙(β-TCP)/聚-L-乳酸(PLLA)复合材料及新型可吸收骨折内固定器。方法:通过研磨方法制备β-TCP超细粒子,用一缩二乙二醇作分散剂研磨β-TCP后,再将β-TCP与PLLA超声混合,制得复合材料,经注塑加工制成可吸收骨钉,并采用扫描电镜等方法进行表征。结果与结论:用一缩二乙二醇作分散剂研磨β-TCP后再经超声混合,可以使β-TCP超细粒子在复合材料中分散均匀,粒子大小仅为300nm左右,β-TCP与PLlA基体之间结合良好。超细β-TCP/PLLA复合材料可加工成可吸收骨钉,弯曲强度达到100MPa左右,完全满足松质骨内固定的要求。 相似文献
10.
MN Tabrizi† C Chams-Davatchi† N Esmaeeli† P Noormohammadpoor† F Safar† H Etemadzadeh† HA Ettehadi‡ F Gorouhi† 《Journal of the European Academy of Dermatology and Venereology》2007,21(1):79-84
BACKGROUND: Pemphigus vulgaris (PV) is a severe blistering disease involving the skin and mucous membranes. The most common causes of death in these patients are adverse effects of drugs, and infection. Skin lesions are one of the important sources of infection. Thus, any local treatment that could reduce healing time of lesions and consequently reduce the total dosage of drugs needed to treat is favourable. OBJECTIVE: To evaluate the efficacy of epidermal growth factor (EGF) in reducing healing time of lesions in patients with pemphigus vulgaris. METHODS: In this randomized, double-blind, within-patient, left/right, controlled trial, 20 hospitalized patients with pathologial and immunohistologial (direct and indirect immunoflourecence) proven pemphigus vulgaris (PV) were chosen. In addition, all patients had at least one appropriate pemphigus lesion on each side of the body that had not healed after 2-week systemic therapy and sterile saline washing. EGF (10 microg/g) in 0.1% silver sulfadiazine cream vs. 0.1% silver sulfadiazine cream alone was applied randomly on one side of the body. RESULTS: Kaplan-Meier survival analysis suggested that median time to heal with application of EGF plus silver sulfadiazine cream was 9 days, in comparison with 15 days for silver sulfadiazine cream alone (log-rank test, P=0.0003). No intervention-related adverse effect was observed during the study. CONCLUSIONS: EGF can significantly reduce healing time of skin lesions in patients with pemphigus vulgaris, at least when this cream base is applied (Cochrane skin group identifier: CSG20). 相似文献